Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinyi San is a traditional Chinese medicine (TCM) formula, also known as Magnolia Flower Powder, primarily indicated for the treatment of allergic rhinitis and chronic sinusitis, particularly the "lung qi deficiency and cold" type. The formula is a combination of several botanical ingredients, typically including *Magnolia biondii* (Xinyi), *Angelica dahurica* (Baizhi), and *Mentha haplocalyx* (Bohe), which work synergistically to dispel wind-cold, reduce nasal congestion, and modulate the immune response. Clinical research, such as that conducted by Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, evaluates modified granule formulations of Xinyi San to compare their efficacy and safety against traditional decoctions and standard Western medical treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xinyi San.